Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asthma Trials May Need More Pediatric Focus After GSK’s Mepolizumab, Breo Ellipta Woes

Executive Summary

Mepolizumab seems headed for approval in severe asthma – but only in adults; adolescent data in pivotal studies were promising, but too limited.

Advertisement

Related Content

Breo Ellipta Stumbles On Pediatric Asthma Claim, But Advair Helps Break The Fall
FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056944

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel